PHAXIAM Therapeutics announces the enrolment of the first patient in its phase 1 trial in infective endocarditis caused by Staphylococcus aureus
The study will enrol 12 patients in 5 French clinical centres
Initial results expected in Q3 2024
This study will enable us to evaluate the intravenous administration of phages, which is particularly well-suited to indications where the medical stakes are very high